Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics
Open Access
- 26 November 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (12) , 1144
Abstract
The discovery and development of effective analgesics is greatly lagging behind the steadily rising prevalence of chronic pain. Currently prescribed analgesics for chronic pain are lacking in efficacy mainly due to their narrowly-targeted mechanism of action. Driving neuronal hyperexcitability that underlies symptoms of chronic pain are multiple non-neuronal processes, among which are tissue hypoxia and oxidative stress. Here we demonstrate the design, synthesis, and activity of new multi-component bi-functional analgesic crystalline solids, co-crystals, and salts, based on pairing of vasodilatory anti-hypoxic drugs pentoxifylline, clonidine and linsidomine with antioxidant nutraceuticals protocatechuic acid, α-lipoic acid, and caffeic acid. After validation, chemical and structural characterization of these novel salts and co-crystals, topical formulations of the products were tested in a rat model of complex regional pain syndrome. Analgesic effects achieved with the salts and co-crystal exceeded the efficacy and/or potency of constituent compounds indicating that more effective, advanced analgesics can readily be developed by careful pairing of compounds that simultaneously target multiple neural and non-neural processes driving chronic pain.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada (RGPIN/05605, RGPIN-2017-06467, RGPAS 507837-17)
- Canadian Institutes of Health Research (MOP-119279)
- Louise and Alan Edwards Foundation (N/A)
This publication has 43 references indexed in Scilit:
- The role of co-crystals in pharmaceutical designTrends in Pharmacological Sciences, 2013
- Drug-drug co-crystalsDARU Journal of Pharmaceutical Sciences, 2012
- Polymorphs, Salts, and Cocrystals: What’s in a Name?Crystal Growth & Design, 2012
- A Hypothesis for the Cause of Complex Regional Pain Syndrome-Type I (Reflex Sympathetic Dystrophy): Pain Due to Deep-Tissue Microvascular PathologyPain Medicine, 2010
- Using Cocrystals To Systematically Modulate Aqueous Solubility and Melting Behavior of an Anticancer DrugJournal of the American Chemical Society, 2009
- Cutaneous Tactile Allodynia Associated with Microvascular Dysfunction in MuscleMolecular Pain, 2008
- Stimulating the development of mechanism-based, individualized pain therapiesNature Reviews Drug Discovery, 2007
- Pharmaceutical Co-CrystalsJournal of Pharmaceutical Sciences, 2006
- Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-Type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the ratPain, 2004
- Clinical Pharmacokinetics of MolsidomineClinical Pharmacokinetics, 1996